N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 1.849 NOK 0.16% Market Closed
Market Cap: 603.8m NOK

Operating Margin
Nykode Therapeutics ASA

-512.8%
Current
-533%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-512.8%
=
Operating Profit
-40.3m
/
Revenue
7.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Nykode Therapeutics ASA
OSE:NYKD
603.8m NOK
-513%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
334.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
160.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
117.5B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD
-5%

Nykode Therapeutics ASA
Glance View

Market Cap
603.8m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
3.787 NOK
Undervaluation 51%
Intrinsic Value
Price
N
What is Intrinsic Value?

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-512.8%
=
Operating Profit
-40.3m
/
Revenue
7.9m
What is the Operating Margin of Nykode Therapeutics ASA?

Based on Nykode Therapeutics ASA's most recent financial statements, the company has Operating Margin of -512.8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 265,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.